CSIMarket
 
Acasti Pharma Inc   (NASDAQ: ACST)
Other Ticker:  
 
 
Price: $3.3700 $-0.03 -0.882%
Day's High: $3.448 Week Perf: 4.66 %
Day's Low: $ 3.20 30 Day Perf: 9.77 %
Volume (M): 28 52 Wk High: $ 3.60
Volume (M$): $ 94 52 Wk Avg: $2.97
Open: $3.38 52 Wk Low: $2.13



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 11
 Employees 20
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Acasti Pharma Inc
Acasti Pharma Inc is a pharmaceutical company that specializes in the research and development of prescription drugs for various medical conditions. The company is known for its focus on developing innovative treatments for cardiovascular diseases, including a particular emphasis on the use of omega-3 fatty acids. Acasti Pharma aims to provide safe and effective pharmaceutical solutions to improve the quality of life for patients suffering from these conditions. The company is based in Canada and operates with a vision to become a global leader in cardiovascular drug development.


   Company Address: 103 Carnegie Center Suite 300 Princeton 8540 NJ
   Company Phone Number: 839-4378    Stock Exchange / Ticker: NASDAQ ACST


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRN   -2.01%    
BMRN        2.36% 
FOLD   -2.85%    
RARE   -5.13%    
SRPT   -2.05%    
VRTX   -5.81%    
• View Complete Report
   



Management Announcement

Grace Therapeutics Emerges from the Shadows of Acasti: A New Name and New Hope Amid Financial Hurdles and Promising Clinical Trials,

Published Fri, Oct 25 2024 12:00 PM UTC

In a decisive move signaling its commitment to revitalization and growth, Acasti Pharma Inc. has officially announced a corporate name change to Grace Therapeutics, Inc. This strategic rebranding reflects the extensive scientific and corporate brand equity that has been established previously under the name Grace Therapeutics. Amid this transformative leadership shift, Acast...

Product Service News

Acasti Pharma Balancing Clinical Progress with Financial Challenges

Published Wed, Sep 25 2024 11:30 AM UTC

Acasti Announces Completion of Patient Enrollment in Phase 3 STRIVE-ON Safety TrialAcasti Pharma Inc., a biopharmaceutical innovator, has announced the completion of patient enrollment for its pivotal Phase 3 STRIVE-ON safety trial of GTX-104. The trial aims to assess the safety profile of GTX-104, a novel formulation designed for specific therapeutic use. According to Acas...

Clinical Study

Acasti Pharma Advances Phase 3 STRIVE-ON Safety Trial Enrollment and Remains on Track for NDA Submission

Published Thu, Jun 27 2024 8:05 PM UTC

In an exciting development, Acasti Pharma Inc. has announced that it has successfully achieved 50% enrollment in its pivotal Phase 3 STRIVE-ON safety trial. This milestone marks a significant step forward for the biopharmaceutical company in its mission to develop innovative therapies for patients.The STRIVE-ON trial aims to evaluate the safety and efficacy of Acasti s poten...

Product Service News

Acasti Pharma Showcases Novel Treatment for Rare Disease at BIO International Convention

Published Tue, May 28 2024 8:05 PM UTC

Acasti Pharma Inc. (Nasdaq: ACST), a late-stage biopharma company, is set to participate in the highly anticipated BIO International Convention, to be held at the San Diego Convention Center from June 3-6, 2024. The company will utilize this platform to present its groundbreaking injectable formulation, GTX-104, which addresses the high unmet medical needs associated with an...

Acasti Pharma Inc

Acasti Pharma Inc Reveals Operating Loss of $2.092 Million in Sep 30 2023 Report

Acasti Pharma Inc Shows Promising Signs of Recovery with Improved Financials
The Major Pharmaceutical Preparations sector has been closely watched by investors and market analysts for its potential to yield significant returns. Among the key players in this sector, Acasti Pharma Inc (ACST) stands out as a rising star, as indicated by its recent financial reports.
In the second quarter of 2024, Acasti Pharma Inc reported an operating loss of $-2.092 million, a significant improvement from the operating loss of $-5.108 million in the same period of 2022. This positive development signals a step in the right direction for the company.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com